Efficacy and safety of a new prolonged release formulation of alfuzosin 10 mg once daily versus alfuzosin 2.5 mg thrice daily and placebo in patients with symptomatic benign prostatic hyperplasia. ALFORTI Study Group. (Q53338003)
Jump to navigation
Jump to search
scientific article published in March 2000
Language | Label | Description | Also known as |
---|---|---|---|
English | Efficacy and safety of a new prolonged release formulation of alfuzosin 10 mg once daily versus alfuzosin 2.5 mg thrice daily and placebo in patients with symptomatic benign prostatic hyperplasia. ALFORTI Study Group. |
scientific article published in March 2000 |
Statements
Efficacy and safety of a new prolonged release formulation of alfuzosin 10 mg once daily versus alfuzosin 2.5 mg thrice daily and placebo in patients with symptomatic benign prostatic hyperplasia. ALFORTI Study Group. (English)
P van Kerrebroeck
A Jardin
K U Laval
P van Cangh
1 March 2000
37
3
306-313